Literature DB >> 23880626

Use of the noninvasive entero-test in the detection of Helicobacter pylori in children in an endemic area in Colombia.

Richard N Arboleda1, Barbara G Schneider, Luis E Bravo, Judith Romero-Gallo, Richard M Peek, Robertino M Mera, Maria Clara Yepez, Cristina Campo, Pelayo Correa.   

Abstract

BACKGROUND AND
OBJECTIVE: Gastric infection with Helicobacter pylori (H pylori), a strong risk factor for gastric cancer, is highly prevalent in children residing in the Colombian Andes. We aimed to validate the use of the Entero-test to culture and genotype H pylori strains from asymptomatic Colombian children.
METHODS: Children (ages 10-15 years, n = 110, 80 of which were H pylori positive by the urea breath test [UBT]) were subjected to the Entero-test, and strings were cultured and/or used for DNA extraction for polymerase chain reaction (PCR). These children had been treated for H pylori in 2007. A second population of children (ages 10-15 years, n = 95),which had not been previously treated, was also subjected to the Entero-test.
RESULTS: Of UBT-positive children in the treated group, 29 of 80 (36%) Entero-test samples were H pylori culture positive; 29 additional string extracts were tested by PCR for the H pylori virulence factors cagA and vacA. PCR from cultures and extracts yielded a sensitivity of 74% and specificity of 87%. In the untreated group, 16 of 94 UBT-positive children (17%) produced Entero-tests that were culture positive. Fifty-eight of 94 (62%) string extracts were PCR positive for cagA and/or vacA. In previously treated children, H pylori strains were more often the less virulent vacA s2 (P = 0.001), m2 (P = 0.006), and i2 genotypes (P = 0.039).
CONCLUSIONS: The Entero-test may be used as a noninvasive test to detect H pylori in asymptomatic children residing in high-risk areas for gastric cancer. Treatment of H pylori in children was associated with less virulent genotypes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23880626      PMCID: PMC3725653          DOI: 10.1097/MPG.0b013e318293e1e1

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  34 in total

1.  Analyses of the cag pathogenicity island of Helicobacter pylori.

Authors:  N S Akopyants; S W Clifton; D Kersulyte; J E Crabtree; B E Youree; C A Reece; N O Bukanov; E S Drazek; B A Roe; D E Berg
Journal:  Mol Microbiol       Date:  1998-04       Impact factor: 3.501

2.  Geographic distribution of vacA allelic types of Helicobacter pylori.

Authors:  L J Van Doorn; C Figueiredo; F Mégraud; S Pena; P Midolo; D M Queiroz; F Carneiro; B Vanderborght; M D Pegado; R Sanna; W De Boer; P M Schneeberger; P Correa; E K Ng; J Atherton; M J Blaser; W G Quint
Journal:  Gastroenterology       Date:  1999-04       Impact factor: 22.682

3.  Use of a gastric juice-based PCR assay to detect Helicobacter pylori infection in culture-negative patients.

Authors:  H Yoshida; K Hirota; Y Shiratori; T Nihei; S Amano; A Yoshida; O Kawamata; M Omata
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

4.  Breath and string test: a diagnostic package for the identification of treatment failure and antibiotic resistance of Helicobacter pylori without the necessity of upper gastrointestinal endoscopy.

Authors:  Andreas Leodolter; Kathlen Wolle; Ulrike von Arnim; Stefan Kahl; Gerhard Treiber; Matthias-P Ebert; Ulrich Peitz; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

Review 5.  Adverse events of HP eradication: long-term negative consequences of HP eradication.

Authors:  E D Koster
Journal:  Acta Gastroenterol Belg       Date:  1998 Jul-Sep       Impact factor: 1.316

6.  Expanding allelic diversity of Helicobacter pylori vacA.

Authors:  L J van Doorn; C Figueiredo; R Sanna; S Pena; P Midolo; E K Ng; J C Atherton; M J Blaser; W G Quint
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

7.  Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori.

Authors:  L J van Doorn; C Figueiredo; R Sanna; A Plaisier; P Schneeberger; W de Boer; W Quint
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

Review 8.  The vacuolating cytotoxin of Helicobacter pylori.

Authors:  T L Cover
Journal:  Mol Microbiol       Date:  1996-04       Impact factor: 3.501

9.  Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration.

Authors:  J C Atherton; P Cao; R M Peek; M K Tummuru; M J Blaser; T L Cover
Journal:  J Biol Chem       Date:  1995-07-28       Impact factor: 5.157

10.  Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach.

Authors:  M J Blaser; G I Perez-Perez; H Kleanthous; T L Cover; R M Peek; P H Chyou; G N Stemmermann; A Nomura
Journal:  Cancer Res       Date:  1995-05-15       Impact factor: 12.701

View more
  4 in total

1.  Stability of (13) C-Urea Breath Test Samples Over Time in the Diagnosis of Helicobacter pylori.

Authors:  Tsachi Tsadok Perets; Einav Shporn; Doron Boltin; Ram Dickman; Yaron Niv
Journal:  J Clin Lab Anal       Date:  2015-01-19       Impact factor: 2.352

2.  Nanofiber capsules for minimally invasive sampling of biological specimens from gastrointestinal tract.

Authors:  Johnson V John; Alec McCarthy; Yajuan Su; Daniel N Ackerman; S M Shatil Shahriar; Mark A Carlson; St Patrick Reid; Joshua L Santarpia; Wuqiang Zhu; Jingwei Xie
Journal:  Acta Biomater       Date:  2022-05-02       Impact factor: 10.633

Review 3.  Molecular oncology testing in resource-limited settings.

Authors:  Margaret L Gulley; Douglas R Morgan
Journal:  J Mol Diagn       Date:  2014-09-19       Impact factor: 5.568

Review 4.  Non-invasive diagnostic tests for Helicobacter pylori infection.

Authors:  Lawrence Mj Best; Yemisi Takwoingi; Sulman Siddique; Abiram Selladurai; Akash Gandhi; Benjamin Low; Mohammad Yaghoobi; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.